Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-083 open-label extension in FSHD and CMT
2019-000305-79Phase 2Terminated
- Sponsor
- Acceleron Pharma Inc.
- Start
- Apr 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of efmitermant alfa in facioscapulohumeral muscular dystrophy (FSHD), Charcot-Marie-Tooth disease type 1 (CMT1) and Charcot-Marie-Tooth disease type X (CMTX) (2 cohorts), sponsored by Acceleron Pharma Inc. Primary endpoint: Safety. Started Apr 2019; status: terminated.
02
Drugs
efmitermant alfa
03
Conditions
facioscapulohumeral muscular dystrophy (FSHD)Charcot-Marie-Tooth disease type 1 (CMT1)Charcot-Marie-Tooth disease type X (CMTX)
Beyond the preview
Go deeper on 2019-000305-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000305-79.